Since the Drug Supply Chain Security Act (DSCSA) was enacted nearly 10 years ago, healthcare supply chain stakeholders have made steady progress in meeting regularly (through HDA and other settings) to discuss compliance strategies, establish recommended guidelines and build consensus on key milestones.
The emergence of COVID-19 marked the beginning of a public health crisis the scale of which we have never seen. Amid this unprecedented challenge, the pharmaceutical supply chain — powered by distributors — quickly adapted and adjusted to the global pandemic, protecting the steady supply of critical, lifesaving medicines to hospitals, pharmacies, providers and patients.
The HDA Research Foundation recently announced the selection of four inaugural recipients for its graduate-level scholarship. Established in conjunction with HDA’s Convene, the scholarship, sponsored by Teva Pharmaceuticals, is available annually to individuals with at least two years of service working within HDA-member distributor and manufacturer companies.